Multiple stellate keratitis during immune checkpoint inhibitor therapy

Multiple stellate keratitis during immune checkpoint inhibitor therapy

Saved in:

Bibliographic Details
Main Authors:	Isana Nakajima, Hideki Tsuji
Format:	Article
Language:	English
Published:	Elsevier 2025-03-01
Series:	JFO Open Ophthalmology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2949889925000042
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types
by: Jeanne Shen, et al.
Published: (2024-02-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
by: B.E. Nelson, et al.
Published: (2025-03-01)

Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation
by: Chang Liu, et al.
Published: (2021-01-01)

A review of neurological complications of immune-checkpoint inhibitors
by: D. Valančius, et al.
Published: (2021-12-01)

Resistance mechanisms to immune checkpoint inhibitors: updated insights
by: Besan H. Alsaafeen, et al.
Published: (2025-01-01)

Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
by: Fumika Kamitani, et al.
Published: (2025-02-01)

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
by: Toshiaki Tsurui, et al.
Published: (2025-02-01)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
by: Maansi Joshi, et al.
Published: (2020-01-01)

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
by: Douglas B Johnson, et al.
Published: (2024-07-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Yan Xiao, et al.
Published: (2020-01-01)

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
by: Jiayuan Le, et al.
Published: (2025-12-01)

Immunotherapeutic Potential of Lactobacillus Species as Immune Checkpoint Inhibitors in Cancer Immunotherapy
by: Renukadevi J, et al.
Published: (2025-01-01)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
by: Sandra M Herrmann, et al.
Published: (2023-01-01)

Targeting Herpetic Keratitis by Gene Therapy
by: Hossein Mostafa Elbadawy, et al.
Published: (2012-01-01)

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
by: Maki Todo, et al.
Published: (2025-02-01)

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
by: Zixi Wu, et al.
Published: (2025-12-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01)

Case report: Short-course hypofractionated radiation therapy combined with immune checkpoint inhibitors for the treatment of advanced ovarian mucinous cystadenocarcinoma
by: Xinan Wan, et al.
Published: (2025-01-01)

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
by: Ayaka Kawaguchi, et al.
Published: (2025-03-01)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
by: Ryan S. Chiang, et al.
Published: (2020-01-01)

Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01)

Prognostic value of body adipose tissue parameters in cancer patients treated with immune checkpoint inhibitors
by: Yan Li, et al.
Published: (2025-02-01)

Subtle‐but‐smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits
by: Mizuki Ida, et al.
Published: (2022-06-01)

Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
by: Zhijie Liu, et al.
Published: (2022-06-01)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
by: Samuel Kareff, et al.
Published: (2021-02-01)

Case report: Diagnosis of impaired consciousness in a cancer patient using immune checkpoint inhibitors
by: Daniel Cathalifaud, et al.
Published: (2025-01-01)

From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy
by: Anqi Lin, et al.
Published: (2025-12-01)

A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim
by: Joseph Mort, et al.
Published: (2022-01-01)

RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma
by: Sara Egea‐Rodriguez, et al.
Published: (2025-01-01)

Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer
by: Furnback W, et al.
Published: (2025-02-01)

High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC
by: Alexandre Reuben, et al.
Published: (2024-12-01)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
by: Francesca De Felice, et al.
Published: (2015-01-01)

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors
by: Philippe Rochigneux, et al.
Published: (2025-02-01)

Clinical outcomes after immune checkpoint inhibitor-associated acute kidney injury: a cohort study
by: Vin-Cent Wu, et al.
Published: (2025-02-01)

The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment
by: Ze-Tao Zhan, et al.
Published: (2022-01-01)